Drug Trial Radar · NCT07879911
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Nov 30, 2028
Study completion May 30, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy. Participants may be PD-L1 negative; or PD-L1 positive with disease recurrence after PD-1/PD-L1 inhibitor therapy in the neoadjuvant/adjuvant setting; or PD-L1 positive who cannot tolerate PD-1/PD-L1 inhibitor therapy due to other underlying comorbidities. Approximately 550 participants will be enrolled and randomized at a 1:1 ratio to the experimental group or the control group. All enrolled participants will continue study treatment until BICR-confirmed disease progression, no further clinical benefit as judged by the investigator, unacceptable toxicity, withdrawal of informed consent, loss to follow-up, death, or end of study, whichever occurs first. Upon discontinuation of study treatment, participants will complete the end-of-treatment (EOT) visit and safety follow-up. Survival visits will be performed every 3 months (±14 days) after the last study drug administration to collect participants' survival status and information regarding subsequent anti-tumor therapies
Conditions
- Triple Negative Breast Cancer
Interventions
Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043Biological
Add details that will distinguish this intervention from other interventions in this or another clinical study. Participants in the experimental group will receive SYS6043, administered on Day 1 of each cycle,Q3W.
Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin)Drug
Add details that will distinguish this intervention from other interventions in this or another clinical study. Paclitaxel (90 mg/m², intravenous, Days 1, 8, and 15 of each 4 week cycle \[Q4W\]; or 80 mg/m², intravenous, Days 1, 8, and 15 of each 3 week cycle \[Q3W\]); Nab paclitaxel (100 mg/m², intravenous, Days 1, 8, and 15, Q4W); Capecitabine (1000 1250 mg/m², orally, twice daily on Days 1 14, Q3W); Eribulin (1.4 mg/m², intravenous, Days 1 and 8, Q3W); Carboplatin (administered on Day 1 at an area under the curve \[AUC\] of 6, Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) Assessed by BICR per RECIST 1.1Time frame: Up to approximately 5 years
- Overall Survival (OS)Time frame: Up to approximately 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.